Electromed, Inc. (ELMD) Balance Sheet

The asset build has outpaced liability growth by a wide margin, lifting equity from $42.5M to $54.0M while total liabilities rose only $5.9M over the same window, which suggests the franchise is compounding internally rather than borrowing to grow. Notably, this equity expansion occurred alongside roughly $14.2M of buybacks, so the trajectory appears to reflect genuine retained value creation rather than a static capital base.

A PPE base that has hovered between $4.9M and $5.5M for ten quarters, broadly matching depreciation run-rates, implies the manufacturing footprint needs little reinvestment to sustain output, consistent with the thin capex profile seen in cash flow disclosures. The dominance of cash and receivables over tangible assets means reported returns on assets are largely a function of capital deployment choices, not operating asset productivity, so investors should judge ROIC against deployment rather than asset efficiency.

The fact that equity still rose while returning double-digit millions to shareholders suggests periodic net income is more than covering capital returns, a sign of self-funded buyback capacity rather than balance sheet erosion. However, retained earnings dipped from $23.7M in 2024Q4 to $20.6M in 2025Q1 before resuming a climb, a discontinuity that warrants further investigation against the corresponding income statement period.

With essentially no funded debt and a current ratio that has stayed between 4.31 and 6.53 across ten quarters, ELMD appears insulated from refinancing or short-term funding stress in a way that most device peers are not. The trade-off is that this buffer is partly a product of accumulated cash earning limited operating leverage, so the quality of the cushion rests on whether volatile free cash flow, which turned negative in 2026Q1, resumes refilling it.